Espoo, Finland, 2015-03-05 08:00 CET (GLOBE NEWSWIRE) --
Aspocomp Group Plc, Company Announcement, March 5, 2015 at 9:00 a.m.
Aspocomp's Annual Report 2014 has been published in electronic formats. The complete report is attached to this release as a pdf file and is also available on the company’s website at www.aspocomp.com/annual report . Aspocomp’s Annual Report contains the Financial Statements, the report of the Board of Directors, Auditor’s Report and the Corporate Governance Statement, as well as the Remuneration Statement for 2014. The report is available both in Finnish and in English.
Aspocomp’s Corporate Governance Statement 2014 has been published separately from the Board of Director’s report and is also available on the company’s website at www.aspocomp.com/governance.
For further information, please contact Mikko Montonen, CEO,
tel. +358 20 775 6860, mikko.montonen(at)aspocomp.com.
ASPOCOMP GROUP PLC
Mikko Montonen
CEO
Distribution:
Nasdaq OMX Helsinki Ltd
Major media
www.aspocomp.com
Aspocomp – PCB technology company
Aspocomp develops and sells PCB manufacturing services, focusing on the end-to-end fulfillment of customers’ PCB needs. Our seasoned professionals help customers to create the most optimal PCB designs, both in terms of performance and cost. Our trimmed production lines produce the most challenging designs with the shortest lead-times in the industry. Operating as a service business, we provide one-stop access to technology solutions and competitive products for all PCB technologies.
A printed circuit board (PCB) is the principal interconnection method in electronic devices. PCBs are used for electrical interconnection and as a component assembly platform in most electronic applications. Aspocomp’s PCBs are used in many applications, such as telecommunication networks and devices, automotive electronics, security and medical systems, chipset development and industrial automation.
ASPOCOMP'S ANNUAL REPORT AND CORPORATE GOVERNANCE STATEMENT
Top 10 Most Recent News Articles
MRI Surveillance Gains Ground in Lung Cancer Care
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
Trial Disappointment: No Significant Gains in NSCLC
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue ReadingTop 5 Most Recently Viewed Articles
HeartCore's Journey: From Nasdaq Challenges to Growth Potential
HeartCore's Nasdaq Delisting Challenge HeartCore Enterprises, Inc. (NASDAQ:HTCR), a provider of enterprise software and consulting services, is currently facing a significant challenge related to its listing on the Nasdaq Capital Market. The company has received notice of non-compliance with the minimum bid price requirement, which mandates that its stock price must be at...
Continue Reading
Mitchell Capital Expands Portfolio with Optelos Acquisition
Mitchell Capital's New Acquisition of Optelos Mitchell Capital, a prominent private equity firm, recently announced a significant acquisition that marks a pivotal moment for their long-term investment strategy. They have secured a controlling interest in Optelos, a distinguished provider of digital twin platforms that are tailored for enhancing critical infrastructure...
Continue Reading
Tampa Bay Lightning and Scripps Sports Forge Exciting Partnership
Partnership Announcement Between Tampa Bay Lightning and Scripps Sports The Tampa Bay Lightning have officially entered into an exciting multi-year partnership with Scripps Sports. This collaboration signifies a new chapter for the Tampa Bay Lightning, expanding their reach in broadcasting and enhancing viewer engagement with National Hockey League (NHL) games. Through...
Continue Reading
Kazia Therapeutics Sets Meeting with FDA on Glioblastoma Treatment
Kazia Therapeutics Prepares for FDA Meeting on Paxalisib Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is set to meet with the U.S. Food and Drug Administration (FDA) to explore potential pathways for the registration of its innovative drug, Paxalisib, aimed at treating newly diagnosed glioblastoma multiforme (GBM). This crucial...
Continue Reading
Important Notice for Flux Power Investors on Lead Plaintiff Claims
Overview of Flux Power Investor Claims Investors with concerns regarding their investments in Flux Power Holdings, Inc. (NASDAQ: FLUX) have much to consider as recent developments unfold. The national securities law firm, Faruqi & Faruqi, LLP, is actively investigating claims that could impact investor interests and is eager to assist those affected. Critical Investment...
Continue Reading